Cat. No.: HY-N2157

Pteryxin

(Synonyms: (+)-Pteryxin)

1 Cited Publications

Avis client

Based on 1 publication(s) in Google Scholar

Pteryxin ((+)-Pteryxin) is an orally active multi-target inhibitor that targets NF-κB, MAPK, NLRP3 inflammasome, and Nrf2/ARE pathways. Pteryxin is also a BChE inhibitor (IC₅₀=12.96 μg/mL) with a low inhibitory efficiency on AChE. Pteryxin inhibits the Ca²⁺-calcineurin-NFATc1 pathway by blocking NF-κB/MAPK signaling, inhibiting NLRP3 inflammasome activation, and reducing ROS generation, and activates Nrf2-mediated antioxidant enzyme expression. Pteryxin has anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin can be used in the study of inflammatory diseases, osteoporosis, diabetes, and Alzheimer's disease.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.55%
CAS No.: 13161-75-6
Formule: C₂₁H₂₂O₇
Masse moléculaire:386.40

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Pteryxin Chemical Structure

CAS No.: 13161-75-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[5]

BChE

12.96 μg/mL (IC₅₀)

AChE

NLRP3

NFATc1

Nrf2-ARE

Voir tous les produits spécifiques à Isoform Cholinesterase (ChE) :

AChE
BChE

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR) :

Voir tous les produits spécifiques à Isoform p38 MAPK :

In Vitro

MTT cell viability assay:
Pteryxin (5-20 μM; 24 h) has no significant toxicity to RAW264.7 macrophages and BMMs osteoclast precursor cells^[1]^[2].
ELISA inflammatory factor detection:
IL-6 and TNF-α in RAW264.7 cells^[1].
WB protein analysis:
Pteryxin (5-20 μM; 24 h) concentration-dependently downregulates the expression of iNOS, COX-2, p-p38/p-ERK/p-JNK, p-p65 and NLRP3/ASC/Caspase-1 p20 proteins in RAW264.7 cells, and inhibits the expression of NFATc1/c-FOS/CTSK proteins in BMMs cells^[1]^[2].
IF immunofluorescence:
Pteryxin (20 μM; 24 h) blocks NF-κB p65 nuclear translocation and NLRP3/ASC speck formation in RAW264.7 cells, and reduces F-actin ring area and NFATc1 nuclear localization in BMMs cells^[1]^[2].
qPCR gene expression:
Pteryxin (5-20 μM; 24 h) upregulates antioxidant genes such as HO-1, GCLC, and Trxr1 in MIN6 islet cells, and downregulates Acp5/Mmp9/Dc-stamp^[2]^[3] in BMMs cells^[2]^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

BMMs (bone marrow-derived macrophages)
Concentration:

5, 10, 15, 20, 25 μM
Incubation Time:

48-96 h
Result:

Resulted viability >85% at ≤20 μM, while reduced viability by 12% at 25 μM for 96 h, confirming safety for osteoclastogenesis assays.

In Vivo

Acute lung injury (ALI) model:
Pteryxin (5/10 mg/kg; intraperitoneal injection; once a day; 3 days) significantly attenuates LPS (5 mg/kg, i.t.)-induced lung inflammation in C57BL/6 mice, reduces lung wet/dry weight ratio, myeloperoxidase (MPO) activity, inflammatory cell infiltration in bronchoalveolar lavage fluid (BALF), and IL-6/TNF-α levels^[1].
Osteoporosis (OVX) model:
Pteryxin (10 mg/kg; oral; once a day; 8 weeks) significantly inhibits bone loss in ovariectomized C57BL/6 female mice, increases bone mineral density and trabecular number, reduces osteoclast number, and downregulates serum TRACP-5b and CTX-1 levels^[2].
Diabetic nephropathy (DN) model:

Pteryxin (20 mg/kg; gavage; once daily; 12 weeks) improves STZ-induced renal function in db/db mice, reduced urine protein, serum creatinine and urea nitrogen, alleviates glomerular mesangial proliferation and fibrosis, and inhibits renal NF-κB activation and TGF-β1 expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (male, 20-22 g, 8 weeks old), LPS (5 mg/kg, i.t.)-induced ALI^[1]
Dosage:

5 or 10 mg/kg
Administration:

Intraperitoneal injection (i.p.), once daily for 3 days (starting 1 h prior to LPS).
Result:

Decreased lung wet/dry ratio from 5.8±0.3 (LPS group) to 4.3±0.2 (10 mg/kg); reduced MPO activity from 2.5±0.2 U/mg to 1.4±0.1 U/mg, BALF total cells from 1.2×10⁶±0.1×10⁶ to 0.5×10⁶±0.05×10⁶, IL-6 from 850±60 pg/mL to 320±30 pg/mL, TNF-α from 520±40 pg/mL to 210±20 pg/mL.

Chemical Information

CAS No. 13161-75-6
Appearance Solid
Masse moléculaire 386.40
Formule C₂₁H₂₂O₇
Color White to off-white
SMILES

C/C=C(C)\C(O[C@@H]1C2=C3C(C=CC(O3)=O)=CC=C2OC(C)(C)[C@@H]1OC(C)=O)=O
Synonyms

(+)-Pteryxin
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Plants
- Umbelliferae
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Biomed Pharmacother

Pteryxin suppresses osteoclastogenesis and prevents bone loss via inhibiting the MAPK/Ca2+ signaling pathways mediated by ROS. [Abstract]

2023 Sep:165:114898. PMID: 37352699

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (258.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5880 mL

12.9400 mL

25.8799 mL

5 mM

0.5176 mL

2.5880 mL

5.1760 mL

10 mM

0.2588 mL

1.2940 mL

2.5880 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.47 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (288 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhen D, et al. Pteryxin attenuates LPS-induced inflammatory responses and inhibits NLRP3 inflammasome activation in RAW264.7 cells. J Ethnopharmacol. 2022 Feb 10;284:114753. [Content Brief]

[2]. Sun R, et al. Pteryxin suppresses osteoclastogenesis and prevents bone loss via inhibiting the MAPK/Ca2+ signaling pathways mediated by ROS. Biomed Pharmacother. 2023 Sep;165:114898. [Content Brief]

[3]. Taira J, et al. Cytoprotective Effect of Pteryxin on Insulinoma MIN6 Cells Due to Antioxidant Enzymes Expression via Nrf2/ARE Activation. Antioxidants (Basel). 2023 Mar 10;12(3):693. [Content Brief]

[4]. Kiris I, et al. Molecular Effects of Pteryxin and Scopoletin in the 5xFAD Alzheimer's Disease Mouse Model. Curr Med Chem. 2022;29(16):2937-2950. [Content Brief]

[5]. Orhan IE, et al. Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea. Food Chem Toxicol. 2017 Nov;109(Pt 2):970-974. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5880 mL	12.9400 mL	25.8799 mL	64.6998 mL
	5 mM	0.5176 mL	2.5880 mL	5.1760 mL	12.9400 mL
	10 mM	0.2588 mL	1.2940 mL	2.5880 mL	6.4700 mL
	15 mM	0.1725 mL	0.8627 mL	1.7253 mL	4.3133 mL
	20 mM	0.1294 mL	0.6470 mL	1.2940 mL	3.2350 mL
	25 mM	0.1035 mL	0.5176 mL	1.0352 mL	2.5880 mL
	30 mM	0.0863 mL	0.4313 mL	0.8627 mL	2.1567 mL
	40 mM	0.0647 mL	0.3235 mL	0.6470 mL	1.6175 mL
	50 mM	0.0518 mL	0.2588 mL	0.5176 mL	1.2940 mL
	60 mM	0.0431 mL	0.2157 mL	0.4313 mL	1.0783 mL
	80 mM	0.0323 mL	0.1617 mL	0.3235 mL	0.8087 mL
	100 mM	0.0259 mL	0.1294 mL	0.2588 mL	0.6470 mL

Keywords

Pteryxin

1 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Pteryxin

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Inflammasomes related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Pteryxin

Voir tous les produits spécifiques à Isoform Cholinesterase (ChE)

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform NOD-like Receptor (NLR)

Voir tous les produits spécifiques à Isoform p38 MAPK

Activité biologique

Chemical Information

Publications (1)

Solvant et solubilité

Pureté et documentation

Références